Nephromag (Buffered Phosphate Solution | Mertiatide)

Mertiatide provides phosphate ions within a buffered carrier, allowing rapid incorporation into the body's phosphate pool. This supports cellular energy production, bone mineralization, and helps stabilize blood pH while the buffer maintains a physiologic environment during infusion.

The dosage of Nephromag is determined by the prescribing clinician based on the patient’s serum phosphate level, renal function, and overall clinical condition. The prescriber sets the appropriate concentration and infusion rate for each individual case.

Safety data for Nephromag in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Nephromag offers a buffered formulation that helps maintain pH stability during infusion, which can reduce the risk of local irritation compared with non‑buffered phosphate preparations. Clinical choice depends on physician preference, patient tolerance, and specific therapeutic goals.

Nephromag should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Nephromag is given intravenously, typically diluted in compatible IV fluids and infused over a controlled period as directed by the prescriber. Administration rate and volume are adjusted according to the patient’s clinical status and laboratory results.

Serious risks include hyperphosphatemia leading to calcium phosphate precipitation, severe hypocalcemia, and rare anaphylactic reactions. Monitoring serum phosphate and calcium levels during therapy is essential to mitigate these risks.

Nephromag should be avoided in patients with known hyperphosphatemia, uncontrolled calcium disorders, or a history of severe allergic reactions to its components. Clinicians should also exercise caution in individuals with severe renal impairment.